CpG DNA Peptide Conjugate for CTL Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines fail to induce strong, durable CTL responses necessary for effective protection against diseases like HIV, HCMV, and cancer, and existing adjuvants often have side effects or are ineffective.
Innovation Solution
A conjugated vaccine molecule combining an antigenic peptide with a DNA oligomer, specifically a CpG sequence, to enhance immune recognition and response, utilizing phosphodiester or phosphorothioate backbones and optimal CpG motifs to stimulate immune cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional adjuvants are used to stimulate immune response, then immune activation is enhanced, but side effects and toxicity increase
Solution Approach 1:
The invention changes the chemical parameters of the adjuvant by using modified nucleic acid sequences with specific CpG motifs (e.g., 5'-TCGTCGTT-3') and controlled phosphorothioate linkages. These parameter changes create a more specific and safer immune stimulant that activates TLR9 without the severe side effects of traditional adjuvants like aluminum salts or saponins.
Solution Approach 2:
The invention creates a composite vaccine formulation by combining the antigen (peptide or protein) with the CpG-containing oligonucleotide adjuvant in a specific ratio and structure. This composite approach ensures that the adjuvant enhances antigen presentation and CTL response while the specific sequence design minimizes off-target effects and toxicity.
2Ease of operation
If peptide vaccines are administered alone, then the vaccine is simple to administer, but CTL response is weak and not durable
Solution Approach 1:
The invention merges the antigen peptide with the CpG oligonucleotide adjuvant into a single conjugated vaccine molecule or co-administered formulation. This combination ensures that the peptide antigen is presented alongside the immunostimulatory CpG sequences, which activate dendritic cells and enhance cross-presentation to CD8+ T cells, thereby generating strong and durable CTL responses without complicating administration.
3Object-affected harmful factors
If DNA adjuvants are used to promote CTL responses, then safety is improved, but immune activation potency varies with sequence context
Solution Approach 1:
The invention applies local quality by placing CpG motifs (5'-CG dinucleotides) in specific sequence contexts within the oligonucleotide, such as the 5'-TCGTCGTT-3' motif that is recognized by human TLR9. The use of phosphorothioate linkages at specific positions also enhances stability and immune recognition. This localized optimization ensures consistent and potent immune activation while maintaining safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugated vaccine molecules significantly enhance immune responses, providing effective protection against infectious diseases and cancer by inducing potent CTL and T-helper responses with reduced side effects.
Implementation Method 1
Adjuvant activity has been associated with palindromic DNA sequences that contain unmethylated CpG dinucleotides which conform to the general consensus motif of XCGY
Data Source
AI summary
Highly effective vaccine compositions are constructed according to the methods of this invention. The methods are amenable to use with any peptidic antigen sequence and involve covalent attachment of an immunostimulatory nucleotide sequence to an antigenic peptide sequence. Preferred antigenic peptides are fusion peptides made up of one or more CTL epitope peptides in sequence fused to a T helper peptide.